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Acceleration of Chronic Myeloid Leukemia Correlates With Calcitonin Gene Hypermethylation
By Tuula Malinen, Aarno Palotie, Seppo Pakkala, Leena Peltonen, Tapani Ruutu, and Sten-Erik Jansson
Calcitonin gene methylation at CCGG sites was determined in 39 chronic myeloid leukemia patients by isoschizomeric restriction endonuclease analysis. A total of 27 patients were analyzed while still in the chronic phase: 20 patients had a normal gene, and seven had a hypermethylated gene. There were 12 patients initially studied in accelerated or blastic phases. All but one patient showed gene hypermethylation, suggesting a good correlation between gene methylation and disease stage. All five patients who, while still in the chronic phase, had a major 3.1-kb hypermethylated calcitonin gene fragment, accelerated within 2 to 27 months. In consecutively analyzed patients, the initially normal calcito-
HRONIC MYELOID leukemia (CML) is a myelopro-
C liferative disorder clinically characterized by three disease phases. During the initial chronic phase, cell maturation appears nearly normal. Sooner or later immature cells accumulate and the disease enters an intermediate accelerated phase of variable duration. CML terminates in a fulminant blast crisis with the bone marrow crowded with blastic cells.
With the exception of bone marrow transplantation, no treatment has altered the course of CML. While marrow transplantation performed in the chronic phase of the disease may be curative, it is often postponed to avoid transplantation-related morbidity and mortality. If it is postponed until accelerated or blastic phases the results are unsatisfactory.',' Therefore, the timing of bone marrow transplantation is a major issue in the treatment of CML, and the ability to predict the onset of disease acceleration would have an immediate clinical implication.
There are only few laboratory parameters available for the monitoring of the malignant escalation of CML.3-6 The molecular analysis of the breakpoint on chromosome 22 involved in the formation of the cytogenetic hallmark of the disease, the Philadelphia chromosome, may provide new prognostic information. However, the data accumulated so far is controversial.' In this study, a novel way to monitor CML disease activity is reported. It is well known that in various malignant conditions DNA methylation may be abnormal. In acute leukemias, hypermethylation of the calcitonin gene has been reported.8 This occurrence reflects malignant alteration as the calcitonin gene was normally methylated in normal peripheral blood leukocytes, bone marrow cells, CD34-positive hematopoetic precursor cells, and in lymphocytes in benign reactive conditions. Also, CML patients appeared to have a normal gene?
We show here that while calcitonin gene methylation is generally normal during the chronic disease phase, an abnormal hypermethylated pattern appears as CML transits into accelerated and blastic phases.
MATERIALS AND METHODS
The 5' region specific genomic probe for the human calcitonin gene was a generous gift from Drs S. Baylin and B. Nelkin (Johns Hopkins University Oncology Center, Baltimore,
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nin gene changed to a hypermethylated state as the disease escalated. The hypermethylation predicted disease acceleration with a median lead time of 6 months before any morphologic or clinical signs of disease progression were seen. The disease progressed in 8 of 27 patients initially studied in the chronic phase: in only two patients this occurred without predictive methylation changes. The results suggest that the assessment of calcitonin gene methylation status may be a promising tool for monitoring chronic myeloid leukemia disease escalation. 0 1991 by The American Society of Hematology.
MD) and has been previously described.' The L-myc probe was a 3.3-kb cDNA clone (pU313a), kindly provided by Drs T. Makela and K. Alitalo (University of Helsinki, Finland) (unpublished probe, December 1990).
High molecular weight DNA was extracted with repeated phenol-chloroform extractions modified from Vandenplas et al.''A special precaution was taken to avoid an increase in salt concentration because this interfered with the digestions. Approximately 10 pg of DNA was digested using HpaII (12 Ulpg DNA; New England Bio-Labs, Beverly, MA) or MspI (20 Uikg DNA, New England Bio-Labs, internal control) restriction endonucleases for at least 16 hours. To ensure complete cleavage, additional HpaII at 6 Ulpg DNA was added, and the digestion was continued for an extra 2 hours. After digestion the samples were electrophoresed through 0.8% agarose gels, transferred to nylon filters (Hybond N; Amersham, UK) and hybridized in 50% formamide according to standard protocols." The probe was labeled by random priming (BRL, Gaithersburg, MD) to an average specific activity of 2.4 x lo9 cp4k.g DNA. After washing, the filters were exposed for autoradiography or analyzed on a Digiscan (Siemens AG, Erlangen, Germany) computerized analyzer. All samples were analyzed at least twice. Positive and negative control samples were included in each run.
Bone marrow aspirates or peripheral blood samples were collected from CML patients after informed consent. Routinely, the mononuclear cell fraction was separated by sedimentation through Percoll gradients (density 1.068; Pharmacia, Uppsala, Sweden). Alternatively, red blood cells were lysed in 0.84% ammonium chloride and the leukocytes were used for the analysis without further fractionation. The cell composition of the final DNA hybridization studies. use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From sample was determined from May-Griinwald Giemsa-stained sytofuge slides.
Patients. A total of 39 Philadelphia chromosome positive CML patients, treated at the Helsinki University Central Hospital, were studied. The median age was 47 years (range 9 to 82 years). There were 19 female and 21 male patients. The median follow-up from the diagnosis was 53 months (range 8 to 168 months). Twentyseven patients were in the chronic-disease phase when the calcitonin gene methylation analysis was initially conducted. Eight patients progressed later on and four of these were consecutively studied in accelerated and/or blastic phases. Bone marrow transplantation has been performed in six patients. In the remaining 13 patients no clinical signs of acceleration could be detected. Twelve patients were initially seen and studied in the accelerated phase or blast crisis (two lymphatic, six myeloid blast crisis). A total of 11 patients have died during the follow-up period: two in the chronic phase, seven in blast crisis, and two of complications related to bone marrow transplantation.
All six patients who were considered to enter the accelerated phase during the follow-up period became resistant to busulfan and hydroxyurea therapy. In addition, in five of these six patients, the cytogenetic analysis showed a clonal evolution, in three, the relative proportion of blasts was 10% to 30% in the bone marrow aspirate, and one patient showed progressive splenomegaly. The criterion for blast crisis was a relative blast count exceeding 30% in the bone marrow aspirate. Myelofibrosis was diagnosed by routine histologic criteria.
The chi-squared analysis was performed using the "Linkage Utility Program," version 2.4, by J. Ott (University of Columbia, New York, NY).
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RESULTS
It has previously been reported that the human calcitonin gene has several MspI restriction sites, some of which are located in clusters, in the 5' flanking or intron region^.^^" The methylation of CCGG sites can be studied by digestion with HpaII, the isoschizomer of MspI, which fails to cleave the CCGG sequence if the internal cytosine is methylated. With a normally methylated gene, four distinct HpaII restriction fragments (0.5 kb, 0.6 kb, 1.0 kb, and 2.0 kb) can be detected with a 1.7-kb probe for the area used in this study.9 Hypermethylation of the gene is shown by the presence of additional fragments in the 1.0-to 4.0-kb region.
Sixty bone marrow or peripheral blood samples had been collected from 39 CML patients being treated at the hospital during a 3-year period. If these are observed as a cumulative resource of samples, the 5' end methylation of the calcitonin gene was normal in 27 samples, but in 33 samples the HpaII enzyme failed to cleave DNA at one or several potential restriction sites, demonstrating a hypermethylation of the gene. In 14 of these 33 hypermethylated samples, the only fragment showing the hypermethylation was 3.1 kb in size. In eight samples, the 3.1-kb fragment occurred together with an abnormal 2.6-kb fragment, and in one sample together with a 1.6-kb fragment. In six samples, there was only a 2.6-kb fragment and in one, only a 1.3-kb fragment. The final three samples exhibited three or more hypermethylated fragments. The results are shown in detail in Fig 1. To ensure that the HpaII digestion was complete, the filters were rehybridized with an L-myc probe. No signs Calcitonin gene methylation pattems.
of cleavage incompleteness were detected. The methylation of the L-myc gene did not show significant variation on analyzing different kinds of samples.
Initially, samples of 39 CML patients were analyzed. Clinical characteristics of patients, the cellular composition of samples, as well as individual results are shown in Table 1 . The results are further compiled in Table 2 , which also presents the results of the control studies on normal peripheral blood leukocytes and bone marrow cells.
All control samples with normal cells exhibited the expected normal methylation pattern of the calcitonin gene ( Table 2 ). All but 1 of 12 patients initially analyzed in the accelerated or blastic phase exhibited hypermethylation of the gene. On the other hand, a great majority of patients in the chronic phase (20 of 27 patients) had a normal methylation pattern, which thus appears to correlate with the disease phase.
Scrutiny of Table 1 will show that there was a total of 10 patients with a hypermethylated calcitonin gene while still in the chronic phase. The methylation status did not correlate with an excess of blast cells in the sample analyzed: eg, the blast count was, even after fractionation, below 5% in the majority of samples with positive findings. At the time of sampling, the blast count of the patients in the chronic phase was 5% or lower.
Because of the potential prognostic importance, special attention was focused on those patients showing hypermethylation while clinically still in the chronic disease phase. There were 10 such patients: seven initially detected (Table 2) , and three initially normal who turned hypermethylated during consecutive analyses ( Table 1) .
The clinical courses of these 10 patients, as correlated with the size of the most prominent hypermethylated fragment, are presented in Table 3 . The occurrence of a major 3.1-kb hypermethylated fragment may indicate an adverse prognosis. There were five such patients and all progressed during the follow-up period. The lead time between the first 3.1-kb hypermethylation finding and the appearance of clinical signs of disease acceleration was from 2 to 27 months (mean 10 months).
On the other hand, none of the three patients with a major 2.6-kb fragment in the chronic phase showed any signs of progression during the follow-up (range 28 to 31 months).
Hypermethylation of the calcitonin gene as shown by an abnormal 1.3-kb fragment was observed in only one patient, who developed myelofibrosis some 2 years after the finding. Finally, there was a single patient exhibiting two prominent abnormal fragments (2.6 kb and 3.1 kb in size, respectively) of equal intensity in the chronic-disease phase. The patient contracted his disease at the age of 12, with a chronic phase now lasting for more than 15 years.
The question arises as to whether the hypermethylation of the calcitonin gene is an initial characteristic in CML, or whether the hypermethylation develops during the course of the disease as a sign of disease escalation. To answer this question, consecutive studies were performed by repeated sampling during the chronic phase, and as the disease progressed, during accelerated and blastic phases. In 5 of those 20 patients who during initial studies had a normal gene methylation, a hypermethylated pattern appeared, either while the patient was still in the chronic phase or at later stages (Fig 2) .
DISCUSSION
The present results demonstrate that some 90% of those samples collected from patients in later stages of CML had an abnormal calcitonin gene methylation. On the other hand, a clear majority of patients (74%) in the chronic phase of CML exhibited a normal methylation of the calcitonin gene. The methylation of the gene thus clearly correlates with the clinical stage of CML. As in acute leukemias, the abnormal methylation most obviously reflects malignant alteration: in the present study, hypermethylation was not detected in control samples, and it has never been observed in benign leukocytes at any level of differentiati~n?~."
Little is known about the mechanisms of the calcitonin gene hypermethylation phenomenon in hematologic malignancies. However, in CML it is unlikely that calcitonin gene hypermethylation would be a major event in the initial leukemogenesis; rather, it seems to correlate with the escalation of the disease. This correlation was demonstrated by consecutive studies in five patients who, during initial chronic stages of the disease, exhibited a normal gene methylation but later developed an abnormal pattern. The unlikely possibility that the hypermethylation of the gene would be a special characteristic of an already initially existing minor CML subclone cannot be definitely ruled out.
Calcitonin gene hypermethylation encountered during the chronic-disease phase occurred in essentially two config- 2  21  22  23  24  25  26  27  28  29  10  30  31  24  32, 1  2  5  33  34  35  36  37  30  10  38  18  39 PB  PB  BM  BM  PB  BM  PB  PB  PB  PB  PB  PB  PB  BM   <5  <5  <5  <5  <5  5  <5  <5  <5   ND   <5  <5  <5  <5  <5  <5  <5  <5  <5  <5  <5  <5  <5  <5   ND   <5  <5  <5  <5  <5  <5  < 5  <5  <5  <5   ND   <5  <5  <5  5  15  17  5 The figures indicate the number of patients in different CML disease phases with a normal or hypermethylated gene configuration, respectively. The controls represent four blood samples from healthy donors and 17 bone marrow aspirates with normal findings or benign reactive changes. The statistical analysis (chi-squared 14.61, two-sided, P = .00067) indicates a significant difference between chronic and later CML phases.
urations: a minor group of patients exhibited a 2.6-kb fragment and a major group showed a 3.1-kb fragment as their dominant abnormal fragments. The limited number of patients with the 2.6-kb fragment does not merit any conclusions. However, the present data do suggest that the appearance of the 3.1-kb fragment precedes disease progression. It might be regarded as a warning signal preceding any clinical or morphologic signs of disease acceleration by a median of 6 months, and this would allow ample time for the scheduling of bone marrow transplantation. On the other hand, the chronic phase in patients with a normally methylated gene is apparently likely to continue. The , and 27 showed calcitonin gene hypermethylation initially. Patients 4,10, and 18 initially had a normal methylation configuration but turned hypermethylated later in the chronic phase. In patients with multiple hypermethylated fragments, the most prominent fragment is underlined. The follow-up time indicates the time period (in months) between the detection of a hypermethylated fragment and the appearance of clinical signs of disease acceleration or blast crisis, or when there has been no disease progression, the time elapsed since the hypermethylated fragment was detected. Patients 10 and 12 later entered the blastic phase of the disease. disease progressed in 8 of 27 patients initially studied in the chronic phase: in only two patients, this progression occurred without detection of predictive changes in calcitonin gene methylation (patients 5 and 24, Table 1 ). In both cases, the failure to detect alterations in the methylation status could have been due to the long interval between samples (16 and 18 months, respectively).
The definitive reason for the size variation of the hypermethylated fragments remains obscure. The appearance of the 3.1-kb fragment obviously reflects complete methylation of the calcitonin gene. In this case all the potential HpaII restriction sites are methylated. Accordingly, the existence of bands of smaller sizes indicates that some HpaII restriction sites in the particular sample are still unmethylated and thus available for cleavage?
The data presented here and in the report by Nelkin et all3 suggest that the monitoring of disease activity by consecutive analysis of the calcitonin gene methylation status could be of particular clinical use in the selection of patients for and the timing of bone marrow transplantation. Due to the limited number of patients, the data can be regarded as promising thus far. More patients with careful clinical follow-up should to be studied to show the definitive value of the finding.
